ETHICS APPROVAL
All the authors report adherence to ethical standards in the conception
of the study, data collection and writing of the manuscript. IRB-status:
This study was conducted in accordance with the tenets of the
Declaration of Helsinki and was approved by
the
ethics committee of Huzhou Maternity
& Child Health Care Hospital (IRB-2017-R-010).
REFERENCES
1. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al.
The Lower Anogenital Squamous Terminology Standardization Project for
HPV-Associated Lesions: background and consensus recommendations from
the College of American Pathologists and the American Society for
Colposcopy and Cervical Pathology. J Low Genit Tract Dis.
2012;16(3):205-42.
2. Martin CM, O’Leary JJ. Histology of cervical intraepithelial
neoplasia and the role of biomarkers. Best Pract Res Clin Obstet
Gynaecol. 2011;25(5):605-15.
3. Cox JT, Schiffman M, Solomon D, Group A-LTS. Prospective follow-up
suggests similar risk of subsequent cervical intraepithelial neoplasia
grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1
or negative colposcopy and directed biopsy. Am J Obstet Gynecol.
2003;188(6):1406-12.
4. del Pino M, Garcia S, Fuste V, Alonso I, Fuste P, Torne A, et al.
Value of p16(INK4a) as a marker of progression/regression in cervical
intraepithelial neoplasia grade 1. Am J Obstet Gynecol. 2009;201(5):488
e1-7.
5. Castle PE, Gage JC, Wheeler CM, Schiffman M. The clinical meaning of
a cervical intraepithelial neoplasia grade 1 biopsy. Obstet Gynecol.
2011;118(6):1222-9.
6. Kang WD, Ju UC, Kim SM. Is human papillomavirus genotype important in
predicting disease progression in women with biopsy-proven negative or
CIN1 of atypical squamous cell of undetermined significance (ASC-US)
cytology? Gynecol Oncol. 2018;148(2):305-10.
7. Huang EC, Tomic MM, Hanamornroongruang S, Meserve EE, Herfs M, Crum
CP. p16ink4 and cytokeratin 7 immunostaining in predicting HSIL outcome
for low-grade squamous intraepithelial lesions: a case series,
literature review and commentary. Mod Pathol. 2016;29(12):1501-10.
8. Pretorius RG, Peterson P, Azizi F, Burchette RJ. Subsequent risk and
presentation of cervical intraepithelial neoplasia (CIN) 3 or cancer
after a colposcopic diagnosis of CIN 1 or less. Am J Obstet Gynecol.
2006;195(5):1260-5.
9. Berkowitz RP. 2012 updated consensus guidelines for the management of
abnormal cervical cancer screening tests and cancer precursors. Obstet
Gynecol. 2013;122(2 Pt 1):393.
10. Bentley J, Executive Council Of The Society Of Canadian C, Special
C. Colposcopic management of abnormal cervical cytology and histology. J
Obstet Gynaecol Can. 2012;34(12):1188-202.
11. Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F,
et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for
Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low
Genit Tract Dis. 2020;24(2):102-31.
12. Katki HA, Gage JC, Schiffman M, Castle PE, Fetterman B, Poitras NE,
et al. Follow-up testing after colposcopy: five-year risk of CIN 2+
after a colposcopic diagnosis of CIN 1 or less. J Low Genit Tract Dis.
2013;17(5 Suppl 1):S69-77.
13. Fischer RL, Sveinbjornsson G, Hansen C. Cervical sonography in
pregnant women with a prior cone biopsy or loop electrosurgical excision
procedure. Ultrasound Obstet Gynecol. 2010;36(5):613-7.
14. Pretet JL, Jacquard AC, Saunier M, Clavel C, Dachez R, Gondry J, et
al. Human papillomavirus genotype distribution in low-grade squamous
intraepithelial lesions in France and comparison with CIN2/3 and
invasive cervical cancer: the EDiTH III study. Gynecol Oncol.
2008;110(2):179-84.
15. Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer
P, et al. Type-dependent integration frequency of human papillomavirus
genomes in cervical lesions. Cancer Res. 2008;68(1):307-13.
16. Rebolj M, Mathews CS, Pesola F, Cuschieri K, Denton K, Kitchener H,
et al. Age-specific outcomes from the first round of HPV screening in
unvaccinated women: Observational study from the English cervical
screening pilot. BJOG. 2022;129(8):1278-88.
17. Ye J, Cheng B, Cheng YF, Yao YL, Xie X, Lu WG, et al. Prognostic
value of human papillomavirus 16/18 genotyping in low-grade cervical
lesions preceded by mildly abnormal cytology. J Zhejiang Univ Sci B.
2017;18(3):249-55.
18. Haedicke J, Iftner T. A review of the clinical performance of the
Aptima HPV assay. J Clin Virol. 2016;76 Suppl 1:S40-S8.
19. Stoler MH, Wright TC, Jr., Cuzick J, Dockter J, Reid JL, Getman D,
et al. APTIMA HPV assay performance in women with atypical squamous
cells of undetermined significance cytology results. Am J Obstet
Gynecol. 2013;208(2):144 e1-8.
20. Clad A, Reuschenbach M, Weinschenk J, Grote R, Rahmsdorf J,
Freudenberg N. Performance of the Aptima high-risk human papillomavirus
mRNA assay in a referral population in comparison with Hybrid Capture 2
and cytology. J Clin Microbiol. 2011;49(3):1071-6.
21. Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S, et
al. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of
women with ASC-US or LSIL cervical cytology: a meta-analysis of the
diagnostic accuracy. Int J Cancer. 2013;132(1):101-8.
22. Han M, Li J, Austin M, Varma KR, Zhang H, Zhao C. Human
Papillomavirus (HPV) 16 and 18/45 Genotyping-Directed Follow-up of Women
With Messenger RNA HPV-Positive, Cytology-Negative Cervical Screening
Test Results. Am J Clin Pathol. 2020;153(2):243-50.
23. Wang J, Dong J, Zhou Y, Wang K, Pan M, Deng Z, et al. Performance of
human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping
combined with age stratification in the triaging of women with ASC-US
cytology. Gynecol Oncol. 2022;164(3):607-14.
24. Nayar R, Wilbur DC. The Pap test and Bethesda 2014. Cancer
Cytopathol. 2015;123(5):271-81.
25. Reich O, Regauer S, Marth C, Schmidt D, Horn LC, Dannecker C, et al.
Precancerous Lesions of the Cervix, Vulva and Vagina According to the
2014 WHO Classification of Tumors of the Female Genital Tract.
Geburtshilfe Frauenheilkd. 2015;75(10):1018-20.
26. Reuschenbach M, Wentzensen N, Dijkstra MG, von Knebel Doeberitz M,
Arbyn M. p16INK4a immunohistochemistry in cervical biopsy specimens: A
systematic review and meta-analysis of the interobserver agreement. Am J
Clin Pathol. 2014;142(6):767-72.
27. Egemen D, Cheung LC, Chen X, Demarco M, Perkins RB, Kinney W, et al.
Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus
Guidelines. J Low Genit Tract Dis. 2020;24(2):132-43.
28. Mittal S, Basu P, Muwonge R, Banerjee D, Ghosh I, Sengupta MM, et
al. Risk of high-grade precancerous lesions and invasive cancers in
high-risk HPV-positive women with normal cervix or CIN 1 at baseline-A
population-based cohort study. Int J Cancer. 2017;140(8):1850-9.
29. Cortecchia S, Galanti G, Sgadari C, Costa S, De Lillo M, Caprara L,
et al. Follow-up study of patients with cervical intraepithelial
neoplasia grade 1 overexpressing p16Ink4a. Int J Gynecol Cancer.
2013;23(9):1663-9.
30. Hu SY, Rezhake R, Chen F, Zhang X, Pan QJ, Ma JF, et al. Outcomes in
women with biopsy-confirmed cervical intraepithelial neoplasia grade 1
or normal cervix and related cofactors: A 15-year population-based
cohort study from China. Gynecol Oncol. 2020;156(3):616-23.
31. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE,
Lloveras B, et al. Human papillomavirus genotype attribution in invasive
cervical cancer: a retrospective cross-sectional worldwide study. Lancet
Oncol. 2010;11(11):1048-56.